Zentalis Pharmaceuticals, Inc. (ZNTL) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
13/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinZNTL / S&P 107.26% / 15.20% |
LoseZNTL / S&P ZNTL unavailable / 15.00% |
LoseZNTL / S&P -13.72% / 50.40% |
| 2026-Q11/3 |
WinZNTL / S&P 73.33% / -4.33% |
LoseZNTL / S&P ZNTL unavailable / 11.30% |
LoseZNTL / S&P -44.73% / 27.70% |
| 2025-Q40/3 |
LoseZNTL / S&P -10.60% / 2.65% |
LoseZNTL / S&P -100.00% / 9.00% |
LoseZNTL / S&P -18.10% / 13.40% |
| 2025-Q31/3 |
WinZNTL / S&P 30.17% / 8.12% |
LoseZNTL / S&P -33.76% / 4.61% |
LoseZNTL / S&P -16.87% / 13.45% |
| 2025-Q20/3 |
LoseZNTL / S&P -27.04% / 10.94% |
LoseZNTL / S&P -33.76% / 4.83% |
LoseZNTL / S&P -16.91% / 10.63% |
| 2025-Q10/3 |
LoseZNTL / S&P -47.52% / -4.27% |
LoseZNTL / S&P -33.76% / 4.98% |
LoseZNTL / S&P -6.01% / 10.57% |
| 2024-Q40/3 |
LoseZNTL / S&P -17.66% / 2.41% |
LoseZNTL / S&P ZNTL unavailable / 5.25% |
LoseZNTL / S&P -48.90% / 6.15% |
| 2024-Q30/3 |
LoseZNTL / S&P -10.02% / 5.89% |
LoseZNTL / S&P ZNTL unavailable / 5.89% |
LoseZNTL / S&P -46.22% / 6.11% |
| 2024-Q20/3 |
LoseZNTL / S&P -74.05% / 4.28% |
LoseZNTL / S&P ZNTL unavailable / 5.38% |
LoseZNTL / S&P -43.33% / 5.12% |
| 2024-Q10/3 |
LoseZNTL / S&P 4.03% / 10.56% |
LoseZNTL / S&P ZNTL unavailable / 5.71% |
LoseZNTL / S&P -22.38% / 5.59% |
| 2023-Q40/3 |
LoseZNTL / S&P -24.48% / 11.69% |
LoseZNTL / S&P ZNTL unavailable / 6.81% |
LoseZNTL / S&P 0.22% / 7.78% |
| 2023-Q31/3 |
LoseZNTL / S&P -28.89% / -3.27% |
LoseZNTL / S&P ZNTL unavailable / 7.52% |
WinZNTL / S&P -2.32% / -5.03% |
| 2023-Q22/3 |
WinZNTL / S&P 64.01% / 8.74% |
LoseZNTL / S&P ZNTL unavailable / 9.50% |
WinZNTL / S&P 24.03% / -8.57% |
| 2023-Q11/3 |
LoseZNTL / S&P -14.60% / 7.50% |
LoseZNTL / S&P ZNTL unavailable / 10.77% |
WinZNTL / S&P 10.85% / -15.69% |
| 2022-Q41/3 |
LoseZNTL / S&P -7.02% / 7.56% |
LoseZNTL / S&P ZNTL unavailable / 11.88% |
WinZNTL / S&P 19.21% / -17.99% |
| 2022-Q31/3 |
LoseZNTL / S&P -22.92% / -4.88% |
LoseZNTL / S&P ZNTL unavailable / 13.47% |
WinZNTL / S&P 29.86% / -1.41% |
| 2022-Q20/3 |
LoseZNTL / S&P -39.10% / -16.10% |
LoseZNTL / S&P ZNTL unavailable / 13.71% |
LoseZNTL / S&P -13.42% / 11.04% |
| 2022-Q10/3 |
LoseZNTL / S&P -45.11% / -4.60% |
LoseZNTL / S&P ZNTL unavailable / 15.97% |
LoseZNTL / S&P -1.02% / 42.23% |
| 2021-Q41/3 |
WinZNTL / S&P 26.14% / 11.03% |
LoseZNTL / S&P ZNTL unavailable / 15.00% |
LoseZNTL / S&P ZNTL unavailable / 96.40% |
| 2021-Q31/3 |
WinZNTL / S&P 25.26% / 0.58% |
LoseZNTL / S&P ZNTL unavailable / 10.77% |
LoseZNTL / S&P ZNTL unavailable / 69.42% |
| 2021-Q21/3 |
WinZNTL / S&P 22.61% / 8.55% |
LoseZNTL / S&P ZNTL unavailable / 6.58% |
LoseZNTL / S&P ZNTL unavailable / 51.81% |
| 2021-Q10/3 |
LoseZNTL / S&P -16.46% / 6.17% |
LoseZNTL / S&P ZNTL unavailable / -1.06% |
LoseZNTL / S&P ZNTL unavailable / 7.39% |
| 2020-Q41/3 |
WinZNTL / S&P 58.89% / 12.15% |
LoseZNTL / S&P ZNTL unavailable / -3.72% |
LoseZNTL / S&P ZNTL unavailable / -33.42% |
| 2020-Q30/3 |
LoseZNTL / S&P -31.92% / 8.93% |
LoseZNTL / S&P ZNTL unavailable / -2.04% |
LoseZNTL / S&P ZNTL unavailable / -27.10% |
| 2020-Q20/3 |
LoseZNTL / S&P ZNTL unavailable / 20.54% |
LoseZNTL / S&P ZNTL unavailable / -0.46% |
LoseZNTL / S&P ZNTL unavailable / -27.11% |
| 2020-Q10/3 |
LoseZNTL / S&P ZNTL unavailable / -19.60% |
LoseZNTL / S&P ZNTL unavailable / 3.47% |
LoseZNTL / S&P ZNTL unavailable / -14.75% |
| 2019-Q40/3 |
LoseZNTL / S&P ZNTL unavailable / 9.07% |
LoseZNTL / S&P ZNTL unavailable / 5.36% |
LoseZNTL / S&P ZNTL unavailable / 2.99% |
| 2019-Q30/3 |
LoseZNTL / S&P ZNTL unavailable / 1.70% |
LoseZNTL / S&P ZNTL unavailable / 5.02% |
LoseZNTL / S&P ZNTL unavailable / 0.21% |
| 2019-Q20/3 |
LoseZNTL / S&P ZNTL unavailable / 4.30% |
LoseZNTL / S&P ZNTL unavailable / 6.64% |
LoseZNTL / S&P ZNTL unavailable / 8.65% |
| 2019-Q10/3 |
LoseZNTL / S&P ZNTL unavailable / 13.65% |
LoseZNTL / S&P ZNTL unavailable / 8.12% |
LoseZNTL / S&P ZNTL unavailable / 14.29% |
| 2018-Q40/3 |
LoseZNTL / S&P ZNTL unavailable / -13.52% |
LoseZNTL / S&P ZNTL unavailable / 9.05% |
LoseZNTL / S&P ZNTL unavailable / 18.23% |
| 2018-Q30/3 |
LoseZNTL / S&P ZNTL unavailable / 7.71% |
LoseZNTL / S&P ZNTL unavailable / 10.21% |
LoseZNTL / S&P ZNTL unavailable / 19.06% |
| 2018-Q20/3 |
LoseZNTL / S&P ZNTL unavailable / 3.43% |
LoseZNTL / S&P ZNTL unavailable / 9.03% |
LoseZNTL / S&P ZNTL unavailable / 14.46% |
| 2018-Q10/3 |
LoseZNTL / S&P ZNTL unavailable / -0.76% |
LoseZNTL / S&P ZNTL unavailable / 7.68% |
LoseZNTL / S&P ZNTL unavailable / 12.46% |
| 2017-Q40/3 |
LoseZNTL / S&P ZNTL unavailable / 6.64% |
LoseZNTL / S&P ZNTL unavailable / 7.03% |
LoseZNTL / S&P ZNTL unavailable / 13.82% |
| 2017-Q30/3 |
LoseZNTL / S&P ZNTL unavailable / 4.48% |
LoseZNTL / S&P ZNTL unavailable / 5.68% |
LoseZNTL / S&P ZNTL unavailable / 17.57% |
| 2017-Q20/3 |
LoseZNTL / S&P ZNTL unavailable / 3.09% |
LoseZNTL / S&P ZNTL unavailable / 4.83% |
LoseZNTL / S&P ZNTL unavailable / 17.74% |
| 2017-Q10/3 |
LoseZNTL / S&P ZNTL unavailable / 6.07% |
LoseZNTL / S&P ZNTL unavailable / 3.67% |
LoseZNTL / S&P ZNTL unavailable / 13.32% |
| 2016-Q40/3 |
LoseZNTL / S&P ZNTL unavailable / 3.82% |
LoseZNTL / S&P ZNTL unavailable / 2.09% |
LoseZNTL / S&P ZNTL unavailable / 7.05% |
| 2016-Q30/3 |
LoseZNTL / S&P ZNTL unavailable / 3.85% |
LoseZNTL / S&P ZNTL unavailable / 0.20% |
LoseZNTL / S&P ZNTL unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ZNTL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 129.59% | 20.78% |
| Annualized return | 129.59% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ZNTL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -94.22% | 83.14% |
| Annualized return | -43.45% | 12.86% |
10Y · 2020-04-03 to 2026-08-27
| Metric | ZNTL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -83.28% | 319.30% |
| Annualized return | -16.38% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |